Patents Assigned to KAHR Medical LTD.
  • Publication number: 20240076346
    Abstract: Type I membrane proteins heterodimers are provided. Accordingly, there is provided a heterodimer comprising two polypeptides selected from the group consisting of SIRPalpha, PD1, TIGIT, LILRB2 and SIGLEC10, wherein each of the two polypeptides is capable of binding a natural binding pair thereof, and wherein the heterodimer does not comprise an amino acid sequence of a type II membrane protein capable of binding a natural binding pair thereof. Also provided are nucleic acid constructs and systems encoding the heterodimer, host-cells expressing same and methods of use thereof.
    Type: Application
    Filed: January 13, 2021
    Publication date: March 7, 2024
    Applicants: KAHR Medical Ltd., Thomas Jefferson University
    Inventors: Ami TAMIR, Mark L. TYKOCINSKI, Edwin BREMER
  • Patent number: 11897937
    Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: February 13, 2024
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Publication number: 20240010700
    Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.
    Type: Application
    Filed: June 21, 2023
    Publication date: January 11, 2024
    Applicant: KAHR Medical Ltd.
    Inventors: Mark L. TYKOCINSKI, Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Patent number: 11702458
    Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: July 18, 2023
    Assignee: KAHR Medical Ltd.
    Inventors: Mark L. Tykocinski, Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Publication number: 20230220040
    Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.
    Type: Application
    Filed: January 26, 2023
    Publication date: July 13, 2023
    Applicant: KAHR Medical Ltd.
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Publication number: 20230048361
    Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising adding to immune cells comprising T cells obtained from a subject having a pathology a non-cellular agent capable of binding 4-1BB and activating said 4-1BB signaling pathway; and culturing the immune cells with said agent for more than 7 days. Also provided are T cells obtainable by the method and uses thereof.
    Type: Application
    Filed: December 30, 2020
    Publication date: February 16, 2023
    Applicants: KAHR Medical Ltd., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Senthil Kumar MUTHUSWAMY, Manuel HIDALGO MEDINA, Qingda MENG, Yaron PEREG, Ayelet CHAJUT
  • Publication number: 20230048719
    Abstract: Methods of culturing T cells with a 4-1BBL fusion polypeptide are provided. Accordingly there is provided a method of culturing T cells comprising adding to immune cells comprising T cells obtained from a subject having a pathology a PD1-4-1BBL or a SIRPalpha-4-1BBL fusion polypeptide; and culturing the immune cells with the fusion polypeptide for more than 7 days. Also provided are T cells obtainable by the method and uses thereof.
    Type: Application
    Filed: December 30, 2020
    Publication date: February 16, 2023
    Applicants: KAHR Medical Ltd., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Senthil Kumar MUTHUSWAMY, Manuel HIDALGO MEDINA, Qingda MENG, Yaron PEREG, Ayelet CHAJUT
  • Patent number: 11566060
    Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: January 31, 2023
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Publication number: 20220267409
    Abstract: Heterodimers are provided. Accordingly, there is provided a heterodimer comprising a dimerizing moiety attached to at least one amino acid sequence of at least one type I membrane protein capable of at least binding a natural ligand or receptor of said at least one type I membrane protein and to at least one amino acid sequence of at least one type II membrane protein capable of at least binding a natural ligand or receptor of said at least one type II membrane protein. Also provided are nucleic acid constructs and systems encoding the heterodimer, host-cells expressing same and methods of use thereof.
    Type: Application
    Filed: July 8, 2020
    Publication date: August 25, 2022
    Applicants: KAHR Medical Ltd., Thomas Jefferson University
    Inventors: Mark L. TYKOCINSKI, Ami TAMIR, Edwin BREMER
  • Publication number: 20220204586
    Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 30, 2022
    Applicant: KAHR Medical Ltd.
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Patent number: 11299530
    Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: April 12, 2022
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Publication number: 20210371500
    Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 2, 2021
    Applicant: KAHR Medical Ltd.
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Patent number: 11130796
    Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: September 28, 2021
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Publication number: 20210284711
    Abstract: PD1-4-1BBL variant fusion proteins are provided. Also provided are isolated polypeptides comprising a PD1 variant or a 4-1BBL variant. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-4-1BBL fusion protein or the isolated polypeptide, host-cells expressing the same and methods of use thereof.
    Type: Application
    Filed: July 11, 2019
    Publication date: September 16, 2021
    Applicant: KAHR Medical Ltd.
    Inventors: Iris PECKER, Itai BLOCH
  • Publication number: 20210214417
    Abstract: SIRPalpha-4-1BBL variant fusion proteins are provided. Also provided are isolated polypeptides comprising a SIRPalpha variant. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-41BBL fusion protein or the isolated polypeptide, host-cells expressing same and methods of use thereof.
    Type: Application
    Filed: July 11, 2019
    Publication date: July 15, 2021
    Applicant: KAHR Medical Ltd.
    Inventors: Iris PECKER, Itai BLOCH
  • Publication number: 20190352371
    Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.
    Type: Application
    Filed: January 4, 2018
    Publication date: November 21, 2019
    Applicant: KAHR Medical Ltd.
    Inventors: Mark L. TYKOCINSKI, Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Publication number: 20190352372
    Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.
    Type: Application
    Filed: January 4, 2018
    Publication date: November 21, 2019
    Applicant: KAHR Medical Ltd.
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Publication number: 20190330304
    Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.
    Type: Application
    Filed: January 4, 2018
    Publication date: October 31, 2019
    Applicant: KAHR Medical Ltd.
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Publication number: 20190016782
    Abstract: A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein.
    Type: Application
    Filed: July 5, 2018
    Publication date: January 17, 2019
    Applicant: KAHR Medical Ltd.
    Inventors: Michal DRANITZKI ELHALEL, Noam SHANI
  • Patent number: 10040841
    Abstract: A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: August 7, 2018
    Assignee: KAHR Medical Ltd.
    Inventors: Michal Dranitzki Elhalel, Noam Shani